HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy

Gene Therapy

Volumn 12, Issue 18, 2005, Pages 1377-1384

  Chattopadhyay, M ^a,b   Krisky, D ^c   Wolfe, D ^c   Glorioso, J C ^c   Mata, M ^a,b   Fink, D J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Diabetic neuropathies; Dorsal root ganglia; HSV; VEGF

Indexed keywords

CALCITONIN; PILOCARPINE; SUBSTANCE P; VASCULOTROPIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CONTROLLED STUDY; DIABETIC NEUROPATHY; EMBRYO; GENE TRANSFER; HERPES SIMPLEX VIRUS; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MALE; MOUSE; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SENSORY NERVE CONDUCTION; SPINAL GANGLION; SWEATING; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ELECTROPHYSIOLOGY; GANGLIA, SPINAL; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MICE; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; SIMPLEXVIRUS; SKIN; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; SIMPLEXVIRUS;

EID: 30744436835     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302533     Document Type: Article

References (51)

1. Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 1997; 46 (Suppl 2): S43-S49.
2. Ishii DN. Implication of insulin-like grwoth factors in the pathogenesis of diabetic neuropathy. Brain Res 1995; 20: 47-67.
3. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong what went right, and what does the future hold? Int Rev Neurobiol 2002; 50: 393-413.
4. Goss JR et al. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neruropathy in streptozotocin-induced diabetes in the mouse. Diabetes 2002; 51: 2227-2232.
5. Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu Rev Microbiol 2004; 58: 253-271.
6. Chattopadhyay M et al. Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain 2004; 127: 929-939.
7. Chattopadhyay M et al. In vivo gene therapy of pyridoxine-induced neuropathy by HSV mediated gene transfer of neurotrophin-3. Ann Neurol 2002; 51: 19-27.
8. Chattopadhyay M et al. Protective effect of HSV mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur J Neurosci 2003; 17: 732-740.
9. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114: 521-532.
10. Hayashi T, Abe K, Itoyama Y. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab 1998; 18: 887-895.
11. Zhang ZG et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106: 829-838.
12. Campbell B, Chuhran C, Lefer AM. Vascular endothelial growth factor attenuates trauma-induced injury in rats. Br J Pharmacol 2000; 129: 71-76.
13. Widenfalk J et al. Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience 2003; 120: 951-960.
14. Schratzberger P et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 2000; 6: 405-413.
15. Antonetti DA et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274: 23463-23467.
16. Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 2004; 101: 11432-11437.
17. Carmeliet P et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439.
18. Breier G, Risau W. The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 1996; 6: 454-456.
19. Couffinhal T et al. Mouse model of angiogenesis. Am J Pathol 1998; 152: 1667-1679.
20. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999; 19: 5731-5740.
21. Hobson MI, Green CJ, Terenghi G. VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J Anat 2000; 197 (Part 4): 591-605.
22. Sun Y et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003; 111: 1843-1851.
23. Yasuhara T et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci 2004; 19: 1494-1504.
24. Azzouz M et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413-417.
25. Samii A, Unger J, Lange W. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett 1999; 262: 159-162.
26. Schratzberger P et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083-1092.
27. Simovic D et al. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001; 58: 761-768.
28. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853-865.
29. Sugihara T, Wadhwa R, Kaul SC, Mitsui Y. A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF 115. J Biol Chem 1998; 273: 3033-3038.
30. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
31. Poltorak Z et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997; 272: 7151-7158.
32. Tischer E et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-11954.
33. Shima DT et al. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996; 271: 3877-3883.
34. Ng YS et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001; 220: 112-121.
35. Houck KA et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-26037.
36. Charnock-Jones DS et al. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod 1993; 48: 1120-1128.
37. de Vries C et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
38. Quinn TP et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993; 90: 7533-7537.
39. Keyt BA et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-7795.
40. Waltenberger J et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-26995.
41. Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 2000; 12: 4243-4254.
42. Soker S et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745.
43. Ishihama H et al. Colocalization of neuropilin-1 and Flk-1 in retinal neovascularization in a mouse model of retinopathy. Invest Ophthalmol Vis Sci 2001; 42: 1172-1178.
44. Kawasaki T et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999; 126: 4895-4902.
45. Hirai A et al. Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves. J Neuroi Sci 2000; 172: 55-62.
46. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996; 47: 1042-1048.
47. Christianson JA, Riekhof JT, Wright DE. Restorative effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice. Exp Neuroi 2003; 179: 188-199.
48. Navarro X, Verdu E, Wendelschafer-Crabb G, Kennedy WR. Immunohistochemical study of skin reinnervation by regenerative axons. J Comp Neurol 1997; 380: 164-174.
49. Krisky DM et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Therapy 1998; 5: 1593-1603.
50. Sweitzer S, Martin D, DeLeo JA. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathy pain. Neuroscience 2001; 103: 529-539.
51. Kennedy WR, Navarro X. Sympathetic sudomotor function in diabetic neuropathy. Arch Neurol 1989; 46: 1182-1186.